Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:34 AM
Ignite Modification Date:
2025-12-25 @ 4:34 AM
NCT ID:
NCT00848718
Eligibility Criteria:
Inclusion Criteria :
* Participants must have locally advanced or metastatic solid tumors.
* Participant is male or female greater than or equal to 18 years of age.
* Participant must have a performance status less than or equal to 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale
* Female participants of childbearing potential has a negative serum or urine pregnancy test within 72 hours prior to receiving the first dose of study medication.
* Participants in the MK-2206 + carboplatin/paclitaxel and MK-2206 + docetaxel treatment arms will be limited to no more than 3 prior cytotoxic therapies for metastatic or recurrent diseases.
* Participant is able to swallow capsules and has no surgical or anatomical condition that will prevent the Participant from swallowing.
Exclusion Criteria:
* Participant has had chemotherapy, radiotherapy or biological therapy within 4 weeks.
* Participants must be least 4 weeks post-surgery and do not expect major surgery in the study duration.
* Participant is currently participating or has participated in a study with an investigational compound or device within 30 days.
* Participant has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
* Participant with a primary central nervous system tumor.
* Participant has known hypersensitivity to the components of study drug.
* Participant has a history or current evidence of heart disease.
* Participant has evidence of clinically significant bradycardia (slow heart rate).
* Participant has uncontrolled high blood pressure.
* Participant at significant risk for hypokalemia (low potassium levels).
* Participant is a known diabetic
* Participant has known psychiatric or substance abuse disorders.
* Participant is a user of illicit drugs.
* Participant is pregnant or breastfeeding.
* Participant is Human Immunodeficiency Virus (HIV) positive.
* Participant has known history of Hepatitis B or C or active Hepatitis A.
* Participant has symptomatic ascites or pleural effusion.
* Participant is receiving treatment with oral corticosteroids.
* Participant is using a potent cytochrome P(450) 3A4 (CYP3A4) inhibitor or inducer.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00848718
Study Brief:
Protocol Section:
NCT00848718